Compare MORN & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MORN | ARWR |
|---|---|---|
| Founded | 1984 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 9.3B |
| IPO Year | 2004 | 2009 |
| Metric | MORN | ARWR |
|---|---|---|
| Price | $183.50 | $70.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $256.50 | $83.40 |
| AVG Volume (30 Days) | 431.2K | ★ 1.6M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | 3.38 | ★ 99.80 |
| EPS | ★ 8.87 | 0.22 |
| Revenue | ★ $2,445,500,000.00 | $16,142,321.00 |
| Revenue This Year | $9.14 | N/A |
| Revenue Next Year | $7.23 | N/A |
| P/E Ratio | ★ $20.06 | $333.23 |
| Revenue Growth | ★ 7.49 | N/A |
| 52 Week Low | $149.08 | $12.44 |
| 52 Week High | $316.71 | $76.76 |
| Indicator | MORN | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 55.76 | 57.49 |
| Support Level | $178.51 | $60.60 |
| Resistance Level | $190.99 | $71.83 |
| Average True Range (ATR) | 6.19 | 3.19 |
| MACD | 0.50 | 0.46 |
| Stochastic Oscillator | 65.21 | 52.91 |
Morningstar Inc is a provider of independent investment research to financial advisers, asset managers, and investors. The company focuses its operations on two core sectors: data and research. It offers data on investments such as mutual funds, stocks, exchange-traded funds, closed-end funds, separate accounts, and variable annuities. Further, the company tracks real-time market data of equity, derivative, currency exchanges, and other investments. In its research operation, Morningstar offers analyst research on passive and active mutual funds, alternative funds, and college saving plans. Morningstar's majority of the revenue is generated in the United States of America.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.